TNXP
Income statement / Annual
Last year (2024), Tonix Pharmaceuticals Holding Corp.'s total revenue was $10.09 M,
an increase of 29.94% from the previous year.
In 2024, Tonix Pharmaceuticals Holding Corp.'s net income was -$130.04 M.
See Tonix Pharmaceuticals Holding Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$10.09 M |
$7.77 M |
$9.03 M |
$0.00 |
$2.91 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$7.77 M
|
$4.74 M
|
$1.00 M
|
$62.86 M
|
$33.49 M
|
$28.83 M
|
$26.32 M
|
$21.29 M
|
$38.97 M
|
$48.16 M
|
| Gross Profit |
$2.33 M
|
$3.03 M
|
$8.03 M
|
-$62.86 M
|
-$30.57 M
|
-$28.83 M
|
-$26.32 M
|
-$21.29 M
|
-$38.97 M
|
-$48.16 M
|
| Gross Profit Ratio |
0.23
|
0.39
|
0.89
|
0
|
-10.49
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$39.97 M
|
$86.66 M
|
$81.88 M
|
$68.84 M
|
$36.16 M
|
$18.19 M
|
$17.56 M
|
$13.34 M
|
$28.53 M
|
$35.50 M
|
| General & Administrative Expenses |
$3.40 M
|
$34.75 M
|
$30.22 M
|
$23.56 M
|
$14.35 M
|
$10.64 M
|
$8.76 M
|
$7.95 M
|
$10.44 M
|
$12.66 M
|
| Selling & Marketing Expenses |
$36.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$40.10 M
|
$34.75 M
|
$30.22 M
|
$23.56 M
|
$14.35 M
|
$10.64 M
|
$8.76 M
|
$7.95 M
|
$10.44 M
|
$12.66 M
|
| Other Expenses |
-$593.00 K
|
$0.00
|
$0.00
|
$29.48 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$80.07 M
|
$121.41 M
|
$112.09 M
|
$92.39 M
|
$50.51 M
|
$28.83 M
|
$26.32 M
|
$21.29 M
|
$38.97 M
|
$48.16 M
|
| Cost And Expenses |
$87.84 M
|
$126.15 M
|
$112.09 M
|
$92.39 M
|
$50.51 M
|
$28.83 M
|
$26.32 M
|
$21.29 M
|
$38.97 M
|
$48.16 M
|
| Interest Income |
$0.00
|
$0.00
|
$1.87 M
|
$106.00 K
|
$48.00 K
|
$210.00 K
|
$233.00 K
|
$168.00 K
|
$127.00 K
|
$108.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$215.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$3.42 M
|
$4.29 M
|
$1.25 M
|
$50.00 K
|
$27.00 K
|
$26.00 K
|
$54.00 K
|
$64.00 K
|
$206.00 K
|
$161.00 K
|
| EBITDA |
-$74.94 M |
-$114.09 M |
-$110.84 M |
-$92.26 M |
-$50.48 M |
-$28.80 M |
-$26.27 M |
-$21.06 M |
-$38.76 M |
-$48.00 M |
| EBITDA Ratio |
-7.42
|
-14.69
|
-12.28
|
0
|
-17.32
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-7.7
|
-15.24
|
-12.41
|
0
|
-17.33
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$52.25 M
|
$1.72 M
|
$1.87 M
|
$25.00 K
|
$48.00 K
|
$210.00 K
|
$233.00 K
|
$168.00 K
|
$127.00 K
|
$108.00 K
|
| Income Before Tax |
-$130.04 M
|
-$116.66 M
|
-$110.22 M
|
-$92.29 M
|
-$50.46 M
|
-$28.62 M
|
-$26.09 M
|
-$21.12 M
|
-$38.84 M
|
-$48.05 M
|
| Income Before Tax Ratio |
-12.88
|
-15.02
|
-12.21
|
0
|
-17.32
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.17 M
|
$0.00
|
$5.40 M
|
$0.00
|
-$7.00 K
|
-$236.00 K
|
$233.00 K
|
-$70.00 K
|
-$206.00 K
|
-$161.00 K
|
| Net Income |
-$130.04 M
|
-$116.66 M
|
-$116.88 M
|
-$92.29 M
|
-$52.17 M
|
-$31.09 M
|
-$29.36 M
|
-$21.12 M
|
-$38.84 M
|
-$48.05 M
|
| Net Income Ratio |
-12.88
|
-15.02
|
-12.95
|
0
|
-17.9
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3504 |
-6368.84 |
-811.68 |
-1666 |
-5056 |
-3866 |
-18064.62 |
-54023.02 |
-199189.74 |
-511212.77 |
| EPS Diluted |
-3504 |
-6368.84 |
-811.68 |
-1666 |
-5056 |
-3866 |
-18064.62 |
-54023.02 |
-199189.74 |
-511212.77 |
| Weighted Average Shares Out |
$2.26 M
|
$1.83 M
|
$3.07 M
|
$7.05 M
|
$2.56 M
|
$804.20 K
|
$162.50 K
|
$39.10 K
|
$19.50 K
|
$9.40 K
|
| Weighted Average Shares Out Diluted |
$2.26 M
|
$1.83 M
|
$3.07 M
|
$7.05 M
|
$2.56 M
|
$804.20 K
|
$162.50 K
|
$39.10 K
|
$19.50 K
|
$9.40 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
